Shortened Flu Symptoms to 3.0 Days1

High-risk patients aged ≥12 years experienced improvement of flu symptoms with XOFLUZA

Single-dose XOFLUZA is the first oral antiviral to demonstrate improvement in flu symptoms over placebo in a clinical study of patients at high risk of developing flu complications.1

XOFLUZA® (baloxavir marboxil) Flu Symptom Alleviation for High Risk Patients in Clinical Trial

Patients at high risk for developing flu complications experienced 28% faster improvement of flu symptoms with single-dose XOFLUZA compared with placebo.1


Who Is Considered High Risk for Flu Complications?5-10*

Millions of people in the United States are at high risk for developing flu complications. These risk factors include:

5 Risks for Serious Flu Complications

In Trial T0832, subjects aged ≥12 years (N=2182) were randomized to receive XOFLUZA 40 mg or 80 mg according to body weight (n=729), oseltamivir 75 mg twice daily for 5 days (n=725), or placebo (n=728). High-risk factors were based on the Centers for Disease Control and Prevention (CDC) definition of health factors known to increase the risk of developing serious complications from influenza, including underlying asthma or chronic lung disease, diabetes, heart disease, morbid obesity, or ≥65 years of age. The primary efficacy endpoint was time to improvement of influenza symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue). This endpoint included alleviation of new symptoms and improvement of any preexisting symptoms that had worsened due to influenza. The median value of the primary endpoint of time to improvement of symptoms (TTIS) with XOFLUZA was 73 hours (95% CI: 67, 85) vs 102 hours (95% CI: 93, 113) with placebo.1

There was no statistically significant difference in the median time to improvement of influenza symptoms in the subjects who received XOFLUZA (73 hours) and those who received oseltamivir (81 hours).1

*Not all high-risk factors, as defined by the CDC, were included in Trial T0832.1,5

Other risk factors in Trial T0832 include Native American or Alaskan Native ancestry, residents of long-term care facilities, neurological/neurodevelopmental conditions, women ≤2 weeks postpartum, metabolic disorders, extreme obesity (body mass index [BMI] ≥40), blood disorders such as sickle cell disease, and persons with immunosuppression.1,11,12

 XOFLUZA® (baloxavir marboxil) Sample Icon

Order a Sample of Single-Dose XOFLUZA

Sample a full course of flu treatment with single-dose XOFLUZA.1

Important Safety Information & Indication


XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for:

  • Treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours and who are:
    • otherwise healthy adults and pediatric patients 5 years of age and older, OR
    • adults and pediatric patients 12 years of age and older who are at high risk of developing influenza-related complications
  • Post-exposure prophylaxis (PEP) of influenza in patients 5 years of age and older following contact with an individual who has influenza.


Limitations of Use
Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.

Important Safety Information

XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme.


Warnings and Precautions

 Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in postmarketing experience with XOFLUZA.  Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected.

Increased Incidence of Treatment-Emergent Resistance in Patients Less Than 5 Years of Age: XOFLUZA is not indicated in patients less than 5 years of age due to increased incidence of treatment-emergent resistance in this age group. In clinical trials, the incidence of virus with treatment-emergent substitutions associated with reduced susceptibility to baloxavir (resistance) was higher in pediatric subjects younger than 5 years of age (43%, 36/83) than in pediatric subjects ≥5 years to <12 years of age (16%, 19/117) or subjects ≥12 years of age (7%, 60/842). The potential for transmission of resistant strains in the community has not been determined.

Risk of bacterial Infections: There is no evidence of the efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

Adverse Reactions

  • The most common adverse reactions (≥1%) in adult and adolescent patients (≥12 years of age) in clinical studies for acute uncomplicated influenza were diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%).
  • The most frequently reported adverse reactions (≥5%) in pediatric patients (5 to <12 years of age) in clinical studies for acute uncomplicated influenza were vomiting (5%) and diarrhea (5%).
  • The safety profile reported in a clinical study for post-exposure prophylaxis was similar in pediatric patients ages 5 to <12 years old as that reported in adults and adolescents 12 years of age and older.

Drug Interactions

Polyvalent cations:
 Coadministration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).


Vaccines: The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and, thereby, decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.

For additional Important Safety Information, please see the XOFLUZA full Prescribing Information.

You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting or calling 1-800-FDA-1088.